AI Article Synopsis
- Degenerative heart valve disease leads to serious health issues, high mortality rates, and increased healthcare costs.
- Transcatheter aortic valve replacement (TAVR) has emerged as a widely accepted treatment option, showing high success rates and minimal complications based on trials and real-world data.
- The article reviews the history of TAVR, current evidence for its use, its limitations, and future prospects for non-surgical treatments of aortic valve disease.*
Article Abstract
Degenerative heart valve disease is associated with significant morbidity and mortality and healthcare expenditures. Transcatheter heart valve repair and replacement has introduced a fundamental change in the therapeutic management and transcatheter aortic valve replacement (TAVR) has gained substantial popularity. Favorable results from randomized trials and large real world registries lead to TAVR being considered a standard procedure with high rates of procedural success and low rates of peri-procedural complications. This article aims to review the past evolution, summarize the available evidence, discuss current indications and limitations and venture a glimpse into the future of percutaneous interventions for aortic valve disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930157 | PMC |
| http://dx.doi.org/10.3389/fcvm.2019.00179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!